Ibarra A, García RI, Rubio JB

Language: Spanish
References: 10
Page: 21-24
PDF size: 36.20 Kb.

ABSTRACT

Hemostasis cell is determined by the expression of proteins at the cell membrane. Proteins that promote the anticoagulant effect include tissue factor, urokinase and plasminogen activator receptor. Cancer patients are at high risk of thrombosis and bleeding. Venous thromboembolism is seen more in solid tumors; however, the presence of intravascular coagulation is seen in hematological cancer, mainly acute leukemia; the incidence varies from 3.87 to 5.79%, and the main factors involved in its pathogenesis are: 1) procoagulant tumor cell, 2) cytotoxic therapy and 3) infectious complications. Immunological activity is decreased in myeloid leukemia patients due to the production of IL10 and tumor necrosis factor (TNF) which decreases directly mobilization of the granules, production of interferon g and cytotoxicity of NK cells. Although there is a high prevalence in the association of antiphospholipid antibodies with acute myeloid leukemia; this has not been associated with an increased risk of thromboembolism.

REFERENCES

1. Nadir Y et al. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica 2005; 90: 1549-1556.

2. Kwann H. Double hazard of thrombophilia and bleeding in leukemia. ASH. Educational book 2007: 151-157.

3. Falanga A et al. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. ASH Educational Book 2007: 165-171.

4. Blom J et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.

5. Kwann H et al. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 2010; 36: 917-924.

6. Baessler T et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010; 115(15): 3058-3069.

7. Szczepanski M et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-1. Haematologica 2011; 96(9): 1302-1309.

8. Xiang et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009; 124(11): 2621-2633.

9. Baessler T et al. Glucocorticoid-induced tumor necrosis factor receptor–related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res 2009; 69: 1037-1045.

10. Lossos I et al. Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Hematol 1998; 57: 139-143.